LEAP2 treatment reduces food intake in an ad libitum meal and lowers postprandial plasma glucose and growth hormone concentrations (Hagemann et al., 2022)Increased plasma LEAP2 levels in obese subjects (Holm et al., 2022; Mani et al., 2019; Andreoli et al., 2024) and in T2DM patients (Li et al., 2022). The gene discussed is GH1; the disease is type 2 diabetes mellitus.